{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Horgan D"],"funding":["Exact Sciences","Astrazeneca","Eli Lilly","F. Hoffman-La Roche","Illumina","Novartis"],"pagination":["72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8780351"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore th"],"journal":["Journal of personalized medicine"],"pubmed_title":["Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe."],"pmcid":["PMC8780351"],"funding_grant_id":["N/A"],"pubmed_authors":["Cufer T","Horgan D","Kerr K","Vainer GW","Rieß O","Ujupan S","Buttner R","Georges N","Conte P","Mastris K","Hofman P","Pinto C","Andre F","Van Meerbeeck J","Penault-Llorca F","Thomas M","Curigliano G","Gallagher WM","Munzone E","Velthaus JL"],"additional_accession":[]},"is_claimable":false,"name":"Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.","description":"Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore th","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-04-08T08:01:27.545Z","creation":"2022-02-11T15:52:10.155Z"},"accession":"S-EPMC8780351","cross_references":{"pubmed":["35055387"],"doi":["10.3390/jpm12010072"]}}